期刊文献+

胃癌中EGFR、HER2及GST-π的表达及临床意义 被引量:3

Expressions and significance of EGFR,HER2 and GST-π in human gastric carcinoma
下载PDF
导出
摘要 目的探讨胃癌组织中人表皮生长因子受体(EGFR)、表皮生长因子受体-2(HER2)、和胎盘型谷胱甘肽-S-转移酶-π(GST-π)的表达及与临床病理特征的关系。方法应用免疫组化Envision二步法,检测70例胃癌组织EGFR、HER2和GST-π的表达情况,并结合其临床病理特点进行分析。结果 EGFR、HER2和GST-π在胃癌组织中的表达阳性率分别为35.7%(25/70)、27.1%(19/70)和58.6%(41/70)。阳性表达与肿瘤分化程度,侵袭深度,有无淋巴结转移及TNM分期有关(P<0.05),而与患者的性别及年龄、肿瘤部位和大小无关(P>0.05)。EGFR、HER2和GST-π三者之间在胃癌组织中的表达均呈正相关(P<0.05)。结论 EGFR、HER2和GST-π的表达参与胃癌的生长、侵袭和转移过程。它们的联合检测有助于胃癌患者靶向药物联合化疗药物的初筛及对胃癌患者的预后评价。 Objective To investigate the expressions of EGFR, HER2 and GST-π in human gastric carcinoma and to study the relationship among them and the elinicopathological factors of gastric carcinoma. Methods The Envision immunohisto- chemical stain method was used to detect EGFR, HER2 and GST-π protein expressions in sample of 70 gastric carcinoma tissues. And their corresponding clinical data were analyzed retrospectively. Results The positive expression rates of EGFR , HER2 and GST-π protein in gastric carcinoma tissues were 35.7% (25/70) ,27. 1% (19/70) and 58.6% (41/70). The positive expression rates were closely relevant to tile differentiation of the carcinoma, invasion depth, lymphatic metastasis and TNM( P 〈 0. 05 ) , but not to the patient's sex, age, tumor site and size (P 〉0.05). There was a stable positive correlation among EGFR , HEir2 and GST-π expressions in gastric carcinoma tissues, respectively. Conclusion EGFR, HER2 and GST-π expressions participate in the development, invasion and metastasis process of gastric carcinoma. Joint detection of them can be looked as a primary detection for guiding the molecular targeting therapy and chemotherapy of gastric carcinoum, and judging the prognosis of gastric carcinoma
出处 《四川医学》 CAS 2012年第12期2034-2036,共3页 Sichuan Medical Journal
基金 四川省卫生厅科研项目(编号:100077)
关键词 胃癌 EGFR HER2 GST-Π 免疫组织化学 gastric carcinoma EGFR HER2 GST-π immunohistochemical
  • 相关文献

参考文献7

  • 1Bang YJ,Van Cutsem E,Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase3,open-label,randomised controlled trial[J].The Lancet,2010,(9742):687-697.
  • 2Pinto C,Di Fabio F,Siena S. Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma[J].Annals of Oncology,2007,(03):510-517.doi:10.1093/annonc/mdl459.
  • 3Abad A. New drugs in the treatment of gastric tumors[J].Clin Transl Oncol,2008,(05):256-261.
  • 4Han SW,Oh DY,Im SA. Phase Ⅱ study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer[J].British Journal of Cancer,2009,(02):298-304.
  • 5Lieto E,Ferraraccio F,Orditura M. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients[J].Annals of Surgical Oncology,2008,(01):69-79.
  • 6吴军,叶正宝,马韬,张俊,朱正纲.西妥昔单抗联合FOLFOX4治疗晚期胃癌一例报道[J].外科理论与实践,2008,13(3):282-283. 被引量:6
  • 7Rasmi Y,Allameh A,Nasseri-Moghaddam S. Comparison of glutathione S-transferase-Pi expression at mRNA levels in oesophagcal mucosa using RT-PCR-ELISA in individuals with reflux diseases,adenocarcinoma and squamous cell carcinoma[J].Clinical Biochemistry,2006,(10):997-1001.doi:10.1016/j.clinbiochem.2006.06.010.

二级参考文献7

  • 1De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients[J]. Br J Cancer,2005,92(9): 1644-1649.
  • 2Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer[J]. J Clin Oncol,2004,22(4):658-663.
  • 3Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract [J]. Oncologist,2008,13(1):39-50.
  • 4Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer[J]. N Engl J Med, 2004,351(4):337-345.
  • 5Lordick F, Lorenzen S, Hegewisch-Becker S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase Ⅱ study of the AIO upper GI study group [C]. Journal of Clinical Oncology,2007,25(18s):4526.
  • 6Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or with- out cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [C]. Journal of Clinical Oncology,2007,25(18s):4000.
  • 7Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J]. J Clin Oncol,2005,23 (9):1803 - 1810.

共引文献5

同被引文献33

  • 1许冬青,佟书娟,詹瑧.表皮生长因子受体在舌癌患者常见舌苔中的表达[J].上海中医药大学学报,2007,21(1):47-49. 被引量:15
  • 2陈涛,李克乾,陈茂华,梁嵘.4400例当代名医医案的舌象分布频数分析[J].辽宁中医杂志,2007,34(9):1217-1220. 被引量:12
  • 3Shiyan L, Pintong H, Zongmin W, et al. The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast- enhanced ultrasonography [J]. Uhrasound Med Biol, 2009, 35(7) : 1086.
  • 4Matsubara J, Yamada Y, Hirashima Y, et al. Impact of insulin -like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer[ J ]. Clin Cancer Res,2008,14(10) :3022.
  • 5Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis[ J]. Eur J Cancer,2001,37(4) :9.
  • 6Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endo- thelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients [ J ]. Ann Surg Oncol,2008,15 ( 1 ) :69.
  • 7Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas : prognostic significance of protein overexpression and high gene copy number[ J ]. Histopathology,2008,52 ( 6 ) :738.
  • 8Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric canc- er patients undergoing curative surgery [ J ]. World J Surg,2007,31 ( 7 ) : 1458.
  • 9Neufeld KL. Nuclear APC[J]. Adv Exp Med Biol,2009,656:13- 29.
  • 10陈斌,罗荣城,陈健鹏,陈晓华.EGFR蛋白在人胃癌组织中的表达及其临床价值[J].肿瘤防治研究,2008,35(2):113-115. 被引量:20

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部